NCT02520869

Brief Summary

All patients will go through an ICSI (intracytoplasmic sperm injection)cycle Monitoring: COH (controlled ovarian hyperstimulation) will be monitored by transvaginal sonography, and then the dose of gonadotropin will be adjusted according to the follicle size and number. Triggering ovulation: when three or more follicles reach \>18mm, endometrium triple line \>8mm, both the gonadotropin and agonist injections will be stopped and 10,000 IU of hCG(human chorionic gonadotropin ) will be given. Egg collection : 34-36 hour after hCG injection, embryo transfer :48-72 hour after oocyte retrieval. Luteal phase support: with 100 mg progesterone injection IM daily until the day of the pregnancy test pregnancy test: 15 days after the embryo transfer. Semen collection and preparation Semen samples will be collected by masturbation in clean containers, usually after 2-3 days of abstinence. Each sample will be allowed to liquefy for at least 20 min at 37 °C. Semen analysis: Basic sperm parameters including sperm count, concentration, motility and morphology will be evaluated according to World Health Organization guidelines. After the initial assessment, ejaculates will be divided into three aliquots. An aliquot of each sample will be used to assess sperm DNA damage, the second aliquot will be processed by direct swim-up technique (n 30) or zeta test technique (n 30) this will be followed by assessment of DNA damage again in each sample to measure the difference in DNA damage after processing in each technique then spermatozoa from the third aliquot will be morphologically analyzed manually using Spermic stain and a light microscope and will be scored according to WHO

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Apr 2014

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2014

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

August 4, 2015

Completed
9 days until next milestone

First Posted

Study publicly available on registry

August 13, 2015

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2016

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2016

Completed
Last Updated

September 20, 2016

Status Verified

September 1, 2016

Enrollment Period

2 years

First QC Date

August 4, 2015

Last Update Submit

September 16, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Percentage of spermatozoa with fragmented DNA before and after processing

    Semen samples will be collected by masturbation in clean containers, usually after 2-3 days of abstinence

    after taking semen sample by 30 minutes

Secondary Outcomes (1)

  • reproductive success

    pregnancy test done 15 days after the embryo transfer.

Study Arms (2)

swim-up

ACTIVE COMPARATOR

swim-up technique for semen processing

Procedure: swim-up technique

zeta test

ACTIVE COMPARATOR

zeta test technique for semen processing

Procedure: zeta test technique

Interventions

swim-up technique used

swim-up

zeta test technique used

zeta test

Eligibility Criteria

Age19 Years - 42 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • written informed consent for the ICSI treatment
  • Female body mass index of 18-30 kg/m2
  • No congenital uterine anomalies in gynecological ultrasound of female partner
  • Male partner not under pharmacological treatment
  • couples undergoes ICSI procedures with ejaculated sperm will be included and - Sperm count not less than 0.1 Million per ML
  • Male abstinence period 2-3 days.

You may not qualify if:

  • women over 42 years old
  • acute infectious diseases
  • systemic illnesses
  • Treatment cycles that will result in a poor ovarian response (\<3 mature oocytes collected) or those involving epididymal, testicular and cryopreserved sperm samples
  • Male patients having varicocele, oligospermia
  • male partner under pharmacological treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Benha Faculty of Medicine

Banhā, El Qaluobia, 13518, Egypt

Location

Study Officials

  • wagdy amer, MD

    lecturer

    PRINCIPAL INVESTIGATOR
  • abo baker el nashar, MD

    professor

    STUDY CHAIR
0

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
lecutrer

Study Record Dates

First Submitted

August 4, 2015

First Posted

August 13, 2015

Study Start

April 1, 2014

Primary Completion

April 1, 2016

Study Completion

May 1, 2016

Last Updated

September 20, 2016

Record last verified: 2016-09

Locations